How does Eli Lilly's triple-agonist stack up against their own dual-agonist?
| Feature | Retatrutide | Tirzepatide |
|---|---|---|
| Developer | Eli Lilly | Eli Lilly |
| Mechanism | GLP-1 + GIP + Glucagon (triple) | GLP-1 + GIP (dual) |
| FDA Status | Not approved (Phase 3) | FDA approved (Mounjaro/Zepbound) |
| Dosing Frequency | Once weekly | Once weekly |
| Maximum Dose | 12 mg (studied) | 15 mg (approved) |
| Weight Loss (trials) | Up to ~24% body weight | Up to ~22% body weight |
| Glucagon Receptor | Yes | No |
| Energy Expenditure Effect | May increase (via glucagon) | Minimal direct effect |
| GI Side Effects | Similar profile | Well-characterized |
| Availability | Research suppliers only | Pharmacies + compounding |
| Cost (compounded) | Higher (limited supply) | Moderate ($40-80/vial) |
Both retatrutide and tirzepatide are developed by Eli Lilly, but they represent different generations of incretin therapy. Tirzepatide targets two receptors (GLP-1 and GIP), while retatrutide adds glucagon receptor activation as a third target.
The glucagon component in retatrutide is theoretically significant because it may increase the body's energy expenditure and promote fat oxidation, addressing weight loss from both sides: reducing intake (appetite suppression) and increasing output (energy expenditure). Phase 2 data supports this with slightly greater weight reduction compared to tirzepatide trials, though direct comparison is complicated by different trial designs.
Tirzepatide is FDA-approved, widely available, and has a well-characterized safety profile. Retatrutide is investigational with limited data. Unless there is a specific reason to try retatrutide (such as inadequate response to tirzepatide), most providers would recommend the approved option.
Of the pairings on this site, retatrutide against tirzepatide is the one where the gap is narrowest. Roughly 24 percent against roughly 22 percent is a much smaller spread than either compound shows against semaglutide, and that has a practical implication: the case for the triple agonist over the dual agonist rests on a difference small enough that trial design could account for much of it.
The comparison is also unusual in that both compounds come from the same developer. Eli Lilly built tirzepatide and is developing retatrutide, which means the two programs share methodology, measurement conventions, and trial infrastructure to a degree that competing companies' programs do not. That makes the numbers somewhat more comparable than a typical cross-trial comparison, though it still is not a head-to-head trial and should not be read as one.
Note also that the dose ceilings run the opposite direction from the outcomes. Retatrutide's studied maximum is 12 mg while tirzepatide's approved maximum is 15 mg, yet retatrutide showed the larger reduction. That is a reminder that milligrams are not a measure of strength across different molecules.
Adding a pathway adds effects, not just benefits. The glucagon component is the source of retatrutide's proposed advantage in energy expenditure, and it is also the part of the profile with the least accumulated human data.
Tirzepatide's dual mechanism has now been characterized across completed Phase 3 programs and post-approval use, so its side effect profile is well mapped: predominantly gastrointestinal, worst after dose increases, easing with adaptation. Retatrutide's Phase 2 work reported a broadly similar gastrointestinal picture, alongside findings including increases in heart rate that Phase 3 is designed to characterize properly.
This is the actual trade being made. It is not "slightly better results for the same risk." It is a modest and not-yet-confirmed efficacy edge, in exchange for a safety profile that has not completed the process tirzepatide has already been through.
For anyone comparing these in practice, availability matters more than the two-percentage-point spread. Tirzepatide can be obtained through a pharmacy with a prescription, in a product whose identity, purity, and concentration are verified. Retatrutide cannot, because it is not approved. Anything available is research-supply material with no equivalent verification.
That difference dominates the comparison. A verified 22 percent is not obviously worse than an unverified 24 percent, because the unverified figure assumes the vial contains what the label claims, at the stated purity, in the stated amount. If it does not, the reconstitution math is wrong by exactly that factor and no calculator on this site or any other can detect it.
Need the broader GLP-1 reference set first? Start with the GLP-1 calculator hub, then move into the individual calculators and comparison pages.
Calculate your dose: Retatrutide calculator | Tirzepatide calculator
This comparison is educational and should be read with product labeling, current clinical literature, and professional guidance where appropriate.